The Lancet· @TheLancet · X·· 2 天前评分90
正文 · 机器翻译
在 #ESMO2026 公布——Izalontamab brengitecan 治疗中国 HR+/HER2– 乳腺癌（PANKU-Breast01）：一项随机、3 期试验 https://spkl.io/60157kJtJ @myESMO
5097 浏览 · 14 赞 · 4 转发 · 0 回复
会议摘要
LBA50按 Proffered paper 1: Breast cancer, early and advanced stage 对上
PANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
https://esmocongress.esmo.org来源：The Lancet · x.com